Close
Sherri Cervantez, MD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Sherri Cervantez, MD
Dr. Sherri Cervantez is a faculty member in the Division of Hematology and Medical Oncology at The University of Texas Health Science Center San Antonio. She earned her bachelor's degree in neuroscience and behavioral biology from Emory University. She received her medical doctorate from Virginia Commonwealth University and completed her residency in internal medicine at West Virginia University. She completed a Hospice and Palliative Medicine fellowship at Virginia Commonwealth University before completing her Hematology and Oncology fellowship at UT Health San Antonio. She joined the Mays Cancer Center, home to UT Health San Antonio MD Anderson, in 2017 as Director of Palliative Oncology. Her clinical interests include lung cancers, head and neck cancers and palliative oncology.
Explore the compassionate and holistic world of palliative care with Dr. Sherri Cervantez on Lung Cancer Foundation of America's Hope With Answers: Living With Lung Cancer.
Gender
- Female
Languages Spoken
- English
-
Credentials
Credentials
Positions
- Assistant Professor, University of Texas Health Science Center San Antonio
- Director of Palliative Oncology, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine
- American Board of Internal Medicine, Hospice & Palliative Medicine
- American Board of Internal Medicine, Oncology
- American Board of Internal Medicine, Hematology
Education
- Medical School: Virginia Commonwealth University, Medical College of Virginia, Richmond, VA
- Residency: West Virginia University Hospital, Morgantown, WV
- Fellowship:
- Virginia Commonwealth University, Medical College, Richmond, VA
- University of Texas Health Science Center San Antonio, San Antonio, TX
- Locations & Contact
-
Research & Publications
Research & Publications
View All Publications - Sherri Cervantez, MD
-
Clinical Trials
Clinical Trials
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sherri Cervantez, MD
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionabl
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Sherri Cervantez, MD
Metabolic kinetic phenotyping to predict cachexia and health outcomes in response to chemoradiation in patients with Head & Neck Cancer
Fifteen patients with advanced H&N cancer who will receive chemoradiation therapy as first line treatment will be studied (as weight loss is expected). The cancer patients will be recruited at the UT Health Mays Cancer Center (MCC) in San Antonio with testing to be performed at the Barshop Institute. The cancer group will be compared to 15 control subjects, recruited at CTRAL (Center for…